Bayer-to-advance-two-first-of-its-kind-cell-and-gene-therapies-for-Parkinsons-disease

Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news